Skip to content

Comparison of Effectiveness of Ondansetron versus Metoclopramide in Hyperemesis Gravidarum

Comparison of Effectiveness of Ondansetron versus Metoclopramide in Hyperemesis Gravidarum

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20190528043735N1
Enrollment
154
Registered
2019-09-30
Start date
2019-06-05
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperemesis gravidarum. Hyperemesis gravidarum with metabolic disturbance

Interventions

Intervention 1: Intervention group: one , intravenous ondansetrone 4 milligram every 8 hours, from the beginning of the stay until patients find oral tolerance. Intervention 2: Intervention group: tw

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: clinical signs of nausea , vomiting and dehydration gestational age <16 weeks from the first day of the last menstruation ketonuria oral intolerance

Exclusion criteria

Exclusion criteria: gastrointestinal disorders justify nausea and vomiting multiple pregnancy having certain diseases, such as diabetes, asthma and urinary tract infection taking any medicine other than folic acid

Design outcomes

Primary

MeasureTime frame
Nausea and vomiting. Timepoint: beginning of study and 24 ,48 hours after starting treatment. Method of measurement: questionnaire PUQE (Pregnancy Unique Quantification of Emesis).

Secondary

MeasureTime frame
Duration of intravenous fluid intake. Timepoint: from start to end of treatment. Method of measurement: review patient medical records and calculate the hours of intake of fluids.;Number of intravenous doses received. Timepoint: from start to end of treatment. Method of measurement: review patient medical records and calculate the number of doses of medication received.;Length of hospitalization. Timepoint: from start to end of treatment. Method of measurement: review patient medical records and calculate the number of hospita admissions days.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Moradiha

Gonabad University of Medical Sciences

moradiha.f@gmu.ac.ir+98 28 3357 9389

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026